Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA

Stanford University

Status: Withdrawn

Conditions: Thyroid Cancer

Treatments: Drug: Iodine-124; Drug: F-18 FDG; Drug: Iodine-123

Study type: Observational

Funder types: Other

Identifiers

NCT00373711

97454 (Other Identifier)

END0003 (Other Identifier)

Details and patient eligibility

About

The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.

Full description

The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.

Conducting this study we hope to find whether I-124 PET/CT allows for detection of more lesions in patients with suspected recurrent thyroid cancer than the current standard of care represented by I-123 WBS and F-18 FDG PET/CT.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:- Patient at Nuclear Medicine clinic at Stanford University Medical Center

• Treated thyroid cancer.
• Detectable levels of Tg.
• Referred for I-123 WBS and F-18 FDG PET/CT for detection of recurrent thyroid cancer.
• Able to have a I-124 PET/CT the day after I-123 WBS and F-18 FDG PET/CT
• Patients older than 18-year-old.
• Patients with history of treated thyroid cancer and suspected recurrent thyroid cancer based on detectable levels of Tg.
• Patients must have I-123 WBS and F-18 FDG PET/CT performed prior to the I-124 PET/CT.
• Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them. Exclusion Criteria:- Patients who are not eligible for I-123 WBS and F-18 FDG PET/CT.
• Patients who cannot complete I-123 WBS and F-18 FDG PET/CT.
• Pregnant women.
• Healthy volunteers.
• Patients participating in other research studies.